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Background
Ibogaine is an alkaloid derived from the African shrub
Tabernanthe iboga. Psychoactive properties of ibogaine
have been known for decades, but more recently the drug
has received much attention because of its promising
“anti-addictive” actions. Thus, ibogaine and its derivatives
are being studied as potential treatment for opioid and sti-
mulant abuse, as well as for alcoholism and smoking.
Because ibogaine has a complex pharmacology and is
known to interact with numerous different cellular targets,
its potential to generate adverse effects is significant.
Besides the expected neurotoxic actions, ibogaine may e.g.
also affect the heart. Thus, several cases of sudden death
after ibogaine use were reported, which have been
hypothesised to be related to cardiac arrhythmias. In
accordance, a severely prolonged QT interval of the elec-
trocardiogram and ventricular tachyarrhythmias were
observed in a woman after she had taken ibogaine.
Methods
To study possible mechanisms by which ibogaine may
trigger cardiac arrhythmias, we explored ibogaine’s
effects on the function of cardiac voltage-gated ion
channels, by using the whole-cell patch-clamp techni-
que. In addition, we also tested the ibogaine derivative
18-methoxycoronaridine (18-MC), which is considered
less toxic.
Results
We found that currents through human ERG (hERG)
potassium channels, heterologously expressed in tsA201
cells, were inhibited by ibogaine in low micromolar con-
centrations (IC50: 3 µM). In addition, ibogaine significantly
altered the hERG channel gating properties. The IC50 of
hERG current inhibition by 18-MC was 15 µM. Heterolo-
gously expressed human NaV1.5 sodium channels were
also affected by ibogaine. For sodium current inhibition
about 25-fold higher ibogaine concentrations were needed
than for hERG. Finally, experiments on isolated adult
mouse cardiomyocytes showed that ibogaine also affects
currents through voltage-gated ion channels in their native
environment.
Conclusions
Because the ibogaine concentrations in animal and
human plasma after ibogaine uptake reach low micromo-
lar concentrations which impair the function of cardiac
ion channels, the drug must be considered a potential
cardiac arrhythmia risk.
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